TRACON Pharmaceuticals Inc (TCON) concluded trading on Wednesday at a closing price of $0.22, with 16.89 million shares of worth about $3.72 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 31.59% during that period and on April 3, 2024 the price saw a loss of about -47.18%. Currently the company’s common shares owned by public are about 44.27M shares, out of which, 40.26M shares are available for trading.
Stock saw a price change of -48.95% in past 5 days and over the past one month there was a price change of 16.45%. Year-to-date (YTD), TCON shares are showing a performance of 25.36% which decreased to -88.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $2.14 during that period. The average intraday trading volume for TRACON Pharmaceuticals Inc shares is 2.98 million. The stock is currently trading -41.94% below its 20-day simple moving average (SMA20), while that difference is down -16.84% for SMA50 and it goes to -8.02% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TRACON Pharmaceuticals Inc (NASDAQ: TCON) currently have 44.27M outstanding shares and institutions hold larger chunk of about 11.23% of that.
The stock has a current market capitalization of $9.99M and its 3Y-monthly beta is at 1.04. It has posted earnings per share of -$0.26 in the same period. It has Quick Ratio of 0.89. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TCON, volatility over the week remained 31.56% while standing at 30.45% over the month.
Stock’s fiscal year EPS is expected to drop by -115.15% while it is estimated to increase by 23.94% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on April 16, 2021 offering a Buy rating for the stock and assigned a target price of $14 to it. Coverage by Maxim Group stated TRACON Pharmaceuticals Inc (TCON) stock as a Buy in their note to investors on February 10, 2021, suggesting a price target of $24 for the stock. On December 23, 2019, H.C. Wainwright Reiterated their recommendations, while on March 01, 2019, Needham Reiterated their ratings for the stock with a price target of $7. Stock get a Buy rating from Stifel on June 13, 2017.
